ALNY up +2.17% percent Today $ALNY High is at 92.8
Post# of 99
Posted On: 11/18/2014 11:42:23 AM
ALNY up +2.17% percent Today $ALNY High is at 92.86 and the Low 89.42 with current volume of 144,011.
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.81 (+0.19), DSX: 7.80 (-0.02), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), ALNY: 89.91 (+0.93), JCP: 7.34 (+0.08), MBLY: 47.60 (+0.62)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.81 (+0.19), DSX: 7.80 (-0.02), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), ALNY: 89.91 (+0.93), JCP: 7.34 (+0.08), MBLY: 47.60 (+0.62)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.85 (+0.94), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), NKE: 96.01 (-0.05), HAL: 49.46 (+0.23), TSN: 42.44 (-0.59), GSAT: 2.57 (-0.23), LULU: 44.82 (+0.40), AGN: 212.00 (+2.80), MACK: 8.81 (+0.19), WHR: 177.55 (+2.00), UA: 68.62 (-0.27), DSX: 7.80 (-0.02), ALNY: 89.91 (+0.93), MPC: 93.58 (+1.07), JCP: 7.34 (+0.08), SHW: 240.43 (+1.12), MBLY: 47.60 (+0.62), REGN: 409.09 (+9.44), BHI: 65.56 (+0.33)
Alnylam Pharmaceuticals Up 45.0% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Mon Nov 17, 5:40PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 45.02% as of today's recent price of $88.98.
ALNY: 89.91 (+0.93)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), AMAG: 36.24 (+1.48), SNY: 48.22 (+0.68)
Alnylam Pharmaceuticals Earnings In Retrospect: Up 2.4% in the Last 12 Days (ALNY)
Comtex SmarTrend(R) - Mon Nov 17, 4:11PM CST
When Alnylam Pharmaceuticals (NASDAQ:ALNY) reported earnings a week ago on November 5th, 2014, analysts, on average, expected the company to report a loss of $0.63 on sales of $8.9 million. The company actually reported a loss of $0.58 per share on sales of $11.0 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Shares of Alnylam Pharmaceuticals have climbed from $88.01 to $90.12, representing a gain of 2.4% since the company reported earnings 12 days ago.
ALNY: 89.91 (+0.93)
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014
Business Wire - Mon Nov 17, 4:00PM CST
--- New Pre-Clinical Data Presented for ALN-AC3 Targeting Apolipoprotein C3, and ALN-ANG Targeting ANGPTL3, Supports Advancement of Both Programs for the Treatment of Genetic and Acquired Dyslipidemias -
ALNY: 89.91 (+0.93)
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VCYT: 6.80 (-0.02), ALNY: 89.91 (+0.93), RTRX: 9.47 (+0.02), VASC: 25.01 (+0.53), DGLY: 11.61 (-0.05)
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 9.27% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:53PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $89.88 to a high of $100.00. Yesterday, the shares fell 9.3%, which took the trading range below the 3-day low of $97.01 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 89.91 (+0.93)
Alnylam Pharmaceuticals (ALNY) Weak On High Volume
at The Street - Fri Nov 14, 9:04AM CST
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate
ALNY: 89.91 (+0.93)
Alnylam reports results from Phase 2 revusiran trial
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:41AM CST
ALNY: 89.91 (+0.93)
Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients
Business Wire - Fri Nov 14, 5:00AM CST
--- After Five Weeks of Treatment, No Significant Changes in Exploratory Clinical Measurements Observed -
ALNY: 89.91 (+0.93)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), ILMN: 189.24 (+6.33), AMAG: 36.24 (+1.48)
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 89.91 (+0.93)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 89.91 (+0.93)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 89.91 (+0.93)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 21.55 (-0.86), BXE: 4.56 (-0.06), ROKA: 3.90 (+0.15), ALNY: 89.91 (+0.93), NCT: 4.74 (+0.03), SSRI: 5.72 (+0.29), ABCB: 25.77 (+0.13), OSIR: 13.26 (-0.04), XCO: 3.06 (-0.01), JDST: 15.42 (-3.17)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), ISIS: 49.67 (+0.66), OGXI: 2.14 (-0.06), TEVA: 57.28 (+0.04), RGLS: 18.28 (+1.43), GSK: 46.22 (+0.34), SNY: 48.22 (+0.68)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 89.91 (+0.93), MDCO: 25.40 (-0.26), SNY: 48.22 (+0.68)
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.81 (+0.19), DSX: 7.80 (-0.02), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), ALNY: 89.91 (+0.93), JCP: 7.34 (+0.08), MBLY: 47.60 (+0.62)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.81 (+0.19), DSX: 7.80 (-0.02), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), ALNY: 89.91 (+0.93), JCP: 7.34 (+0.08), MBLY: 47.60 (+0.62)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.85 (+0.94), BIIB: 303.21 (+0.79), GE: 26.90 (+0.29), NKE: 96.01 (-0.05), HAL: 49.46 (+0.23), TSN: 42.44 (-0.59), GSAT: 2.57 (-0.23), LULU: 44.82 (+0.40), AGN: 212.00 (+2.80), MACK: 8.81 (+0.19), WHR: 177.55 (+2.00), UA: 68.62 (-0.27), DSX: 7.80 (-0.02), ALNY: 89.91 (+0.93), MPC: 93.58 (+1.07), JCP: 7.34 (+0.08), SHW: 240.43 (+1.12), MBLY: 47.60 (+0.62), REGN: 409.09 (+9.44), BHI: 65.56 (+0.33)
Alnylam Pharmaceuticals Up 45.0% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Mon Nov 17, 5:40PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 45.02% as of today's recent price of $88.98.
ALNY: 89.91 (+0.93)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), AMAG: 36.24 (+1.48), SNY: 48.22 (+0.68)
Alnylam Pharmaceuticals Earnings In Retrospect: Up 2.4% in the Last 12 Days (ALNY)
Comtex SmarTrend(R) - Mon Nov 17, 4:11PM CST
When Alnylam Pharmaceuticals (NASDAQ:ALNY) reported earnings a week ago on November 5th, 2014, analysts, on average, expected the company to report a loss of $0.63 on sales of $8.9 million. The company actually reported a loss of $0.58 per share on sales of $11.0 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Shares of Alnylam Pharmaceuticals have climbed from $88.01 to $90.12, representing a gain of 2.4% since the company reported earnings 12 days ago.
ALNY: 89.91 (+0.93)
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014
Business Wire - Mon Nov 17, 4:00PM CST
--- New Pre-Clinical Data Presented for ALN-AC3 Targeting Apolipoprotein C3, and ALN-ANG Targeting ANGPTL3, Supports Advancement of Both Programs for the Treatment of Genetic and Acquired Dyslipidemias -
ALNY: 89.91 (+0.93)
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VCYT: 6.80 (-0.02), ALNY: 89.91 (+0.93), RTRX: 9.47 (+0.02), VASC: 25.01 (+0.53), DGLY: 11.61 (-0.05)
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 9.27% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:53PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $89.88 to a high of $100.00. Yesterday, the shares fell 9.3%, which took the trading range below the 3-day low of $97.01 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 89.91 (+0.93)
Alnylam Pharmaceuticals (ALNY) Weak On High Volume
at The Street - Fri Nov 14, 9:04AM CST
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate
ALNY: 89.91 (+0.93)
Alnylam reports results from Phase 2 revusiran trial
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:41AM CST
ALNY: 89.91 (+0.93)
Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients
Business Wire - Fri Nov 14, 5:00AM CST
--- After Five Weeks of Treatment, No Significant Changes in Exploratory Clinical Measurements Observed -
ALNY: 89.91 (+0.93)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), ILMN: 189.24 (+6.33), AMAG: 36.24 (+1.48)
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 89.91 (+0.93)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 89.91 (+0.93)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 89.91 (+0.93)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 21.55 (-0.86), BXE: 4.56 (-0.06), ROKA: 3.90 (+0.15), ALNY: 89.91 (+0.93), NCT: 4.74 (+0.03), SSRI: 5.72 (+0.29), ABCB: 25.77 (+0.13), OSIR: 13.26 (-0.04), XCO: 3.06 (-0.01), JDST: 15.42 (-3.17)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 303.21 (+0.79), ALNY: 89.91 (+0.93), ISIS: 49.67 (+0.66), OGXI: 2.14 (-0.06), TEVA: 57.28 (+0.04), RGLS: 18.28 (+1.43), GSK: 46.22 (+0.34), SNY: 48.22 (+0.68)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 89.91 (+0.93), MDCO: 25.40 (-0.26), SNY: 48.22 (+0.68)
(0)
(0)